Clinical trials: Liver Hypertrophy
Developmental Delay, Skeletal Abnormalities
Biomarker for Sly Disease (MPS VII) (BioSly)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
- Conditions
- Developmental Delay, Skeletal Abnormalities, Hepatomegaly, Splenomegaly
- Trial name
- BioSly (NCT02298699)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Obesity, Overfeeding
Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation
To investigate metabolic and molecular response to fatty acid-specific overfeeding in overweight subjects, in relation to changes in ectopic fat, lean tissue mass and insulin sensitivity
- Conditions
- Obesity, Overfeeding, Muscle Mass, Body Composition
- Trial name
- LIPOGAIN-2 (NCT02211612)
- Testing
- PUFA-group, SFA-group
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Locally Advanced Malignant Liver Disease
ALPPS: Safety, Feasibility and Efficacy at a Single Center
The possibility to achieve a curative resection in patients with liver malignancies is limited by the future liver remnant (FLR).
- Trial name
- NCT02164292
- Testing
- ALPPS
- Where
- Argentina
- Volunteers
- 30 people
- Sponsor
- Hospital Italiano de Buenos Aires
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatectomy
European SIR-Spheres Surgical Registry
Liver resection is the only curative treatment option for primary and secondary liver tumors. For some primary or secondary malignancies (HCC, NET) liver transplantation is a possible treatment option.
- Trial name
- ESSURE (NCT03912844)
- Testing
- SIRT followed by liver resection or liver transplantation
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- Universitätsklinikum Köln
Hepatomegaly
Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus
To assess the prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus, and to find out it᾿s underlying etiology.
- Trial name
- NCT03666117
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Lesion; Gastrointestinal, Liver, Biliary, Pancreas and Gastrointestinal Disease, Nos
CO2 vs. Air Insufflation for Endoscopic Ultrasound
The insufflation of air in the viscera is indispensable during endoscopy. However, the distension of the bowel that follows is often the cause of abdominal discomfort.
- Trial name
- NCT02773563
- Testing
- EUS with air insufflation, EUS with CO2 insufflation
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Bologna
Liver Resection, Cancer
Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
The aim of this study is to compare two different techniques (portal vein embolization and radiofrequency assisted liver partition with portal vein ligation) for increasing liver volume prior to major liver resection.
- Trial name
- REBIRTH (NCT02216773)
- Testing
- Radiofrequency assisted liver partition with portal vein ligation (RALPP), Portal vein embolization (PVE)
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Imperial College London
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Metastases
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM…
- Trial name
- NCT05195710
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cirrhosis, Carcinoma, Hepatocellular
Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
The purpose of this study is to investigate the impact of splenectomy coupled with portal-azygous disconnection on hepatocarcinogenesis in patients with post-hepatitic cirrhosis after hepatitis B or C virus infection by…
- Conditions
- Liver Cirrhosis, Carcinoma, Hepatocellular, Splenomegaly, Laparotomy
- Trial name
- NCT01201655
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xijing Hospital
Liver Cancer, Cancer of the Liver
4D Phase Contrast MR: Hypertrophy in Liver Cancer
The investigators hypothesize that 4Dimensional Phase Contrast Magnetic Resonance Angiography (4D PC MRA) evaluation of portal venous flow predicts underlying liver function and hypertrophic potential in patients with liver…
- Trial name
- NCT02618447
- Testing
- 4Dimensional Phase Contrast Magnetic Resonance Angiography, Portal vein embolization
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Complication of Transplanted Organ, Nos
Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors
Our objective in this study will be to determine if implementing the glucose/insulin clamp (GICT) on cadaveric organ donors can: Prevent hyperglycaemia Drop in the inflammatory cytokine response after brain death after a minimum…
- Trial name
- NCT01304290
- Testing
- Hyperinsulinemic/normoglycemic clamp
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Gastroesophageal Varices Hemorrhage, Colorectal Cancer
Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices Hemorrhage, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524676
- Testing
- Individualized Treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Zhongshan Hospital
Polycystic Liver Disease, Hepatomegaly
Open-Label Extension of LOCKCYST Trial
Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney
- Trial name
- LOCKCYST-ext (NCT00771888)
- Testing
- lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 54 people
- Sponsor
- Radboud University Medical Center
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Portal Vein Embolization, Liver, Hypertrophy
Comparison of N-butyl-cyanoacrylate and Micro Parti-cles Effect in Inducing Liver Hypertrophy After PVE
The aim of this study is to compare hypertrophy of the FLR after PVE with microparticles to hypertrophy after PVE with cyanoacrylate in a material large enough to answer the study question.
- Trial name
- NCT05660759
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 265 people
- Sponsor
- Linkoeping University
Gastroesophageal Varices, Colorectal Cancer
Early Diagnosis of Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524650
- Testing
- the level of vWF
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Zhongshan Hospital
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
HCC, Resection
Optimizing Y90 Therapy for Radiation Lobectomy
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection.
- Conditions
- HCC, Resection, Transplant, Metastatic Cancer
- Trial name
- NCT04390724
- Testing
- Y90 radioembolization
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Northwestern University